Table 1.

Properties of the different P2Y12 inhibitors. Adapted and modified from [2, 3]

	Clopidogrel	Prasugrel	Ticagrelor
Chemical class	Thienopyridine	Thienopyridine	Cyclopentyl-triazolopyrimidine
Administration	Oral	Oral	Oral
Dose	300–600 mg orally then 75 mg a day	60 mg orally then 10 mg a day	180 mg orally then 90 mg twice a day
Binding reversibility	Irreversible	Irreversible	Reversible
Binding site	ADP-binding site	ADP-binding site	Allosteric binding site
Activation	Prodrug, with variable liver metabolism	Prodrug, with predictable liver metabolism	Active drug, with additional active metabolite
Onset of loading dose effect	2–6 h	30 min	30 min
Duration of effect	3–10 days	7–10 days	3–5 days
Plasma half-life of active P2Y12 inhibitor	30–60 min	30–60 min	6–12 h
Inhibition of adenosine reuptake	No	No	Yes